It looks like NTLA's HAE CRSPR therapy is doomed to fail | BCRX Message Board Posts


BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  12829 of 12832  at  10/31/2022 9:07:38 AM  by

moegrabbedmythumb


It looks like NTLA's HAE CRSPR therapy is doomed to fail

 
Death knell for NTLA's potential CRISPR treatment for HAE: Excepts from two new studies published in Nature Communications in late October 2022: Using the new method, the researchers tested 8,000 potential off-targets for 110 CRISPR guide RNAs in the process of being translated into human medicine. "We found far more off-targets than we would have been able to using existing methods," Gorodkin explains. Furthermore, 37 of these off-targets are located in cancer-related genes, which increases the risk that developing drugs will become harder or even impossible. In addition, unintended cuts in these genes may even lead to cancer as a possible side-effect. phys.org/news/2022-10-break...


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...